drugset / Trial / NCT00016926

Capecitabine in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

NCT00016926 ↗

Treatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating patients who have advanced, persistent, or recurrent cervical cancer.

Timeline

Start
2001-04
Primary completion
2007-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 1800 mg/m2 Oral
Subject Capecitabine Small molecule 2500 mg/m2 Oral

Indications